SeaStar Medical is trading at $4.98, up 6.18%, amid new SCD therapy billing codes, the clearest company-specific context; no source explicitly linked them to the pre-market gain.

  • The codes became available October 1, supporting hospital billing and clinical-outcome reporting. SeaStar says they may expand access to QUELIMMUNE and establish a billing framework for future potential indications.
  • SeaStar announced an October 2 late-breaking presentation at ASN Kidney Week; available information does not establish it as the direct catalyst.